Effect of aspirin therapy on photodynamic therapy with verteporfin for choroidal neovascularization

Retina

Volumn 28, Issue 5, 2008, Pages 711-716

  Ranchod, Tushar M ^a   Guercio, Jason R ^b   Ying, Gui Shuang ^a   Brucker, Alexander J ^a   Stoltz, Robert A ^c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Georgia Retina PC   (United States)

^d Georgia Retina   (United States)

Author keywords

Aspirin; Macular degeneration; Photodynamic therapy; Verteporfin

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CLOPIDOGREL; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN; WARFARIN;

AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; EYE; FEMALE; HUMAN; HYPOTHESIS; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; THROMBOCYTE AGGREGATION; VISUAL ACUITY;

AGED; ASPIRIN; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PLATELET AGGREGATION INHIBITORS; PORPHYRINS; RETREATMENT; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 43249111838     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31816079c3     Document Type: Article

References (13)

1. About Visudyne. Novartis Website. http://www.visudyne.com/info/about/ about-visudyne.jsp January 30, 2006.
2. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-1345.
3. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;119:198-207.
4. Visudyne for injection, package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
5. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748-757.
6. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. Adults behavioral risk factor surveillance system. Am J Prev Med 2006;30:74-77.
7. Born GV, Gorog P, Begent NA. The biologic background to some therapeutic uses of aspirin. Am J Med 1983;74:2-9.
8. Taber SW, Wieman TJ, Fingar VH. The effects of aspirin on microvasculature after photodynamic therapy. Photochem Photobiol 1993;57:856-861.
9. Stern SJ, Craig JR, Flock S, et al. Effect of aspirin on photodynamic therapy utilizing chloroaluminum sulfonated phthalocyanine (CASP). Laser Surg Med 1992;12:494-499.
10. Reed MW, Wieman TJ, Doak KW. The microvascular effects of photodynamic therapy: evidence for a possible role of cyclooxygenase products. Photochem Photobiol 1989;50:419-423.
11. Löw U, Kohlhof JK, Ruprecht KW. Does acetylsalicylic acid have a negative influence on photodynamic therapy? Ophthalmologe 2005;103:204-208.
12. Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization. Ophthalmology 2006;113:2243-2250.
13. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006;124:1532-1542.